Barrios, C. et al. Barriers in access to oncology drugs - a global crisis. Nat. Rev. Clin. Oncol. 20, 7–15 (2023).

Article  CAS  PubMed  Google Scholar 

Cherny, N. I. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed? Nat. Rev. Clin. Oncol. 19, 486–492 (2022).

Article  PubMed  Google Scholar 

Neumann, P. J., Cohen, J. T. & Ollendorf, D. A. The Right Price: A Value-Based Prescription for Drug Costs (Oxford Univ. Press, 2021).

Cai, L. et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: a controlled interrupted time series study. J. Glob. Health 12, 11016 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Li, H. et al. Recent pricing negotiations on innovative medicines pilot in China: experiences, implications, and suggestions. Value Health Reg. Issues 15, 133–137 (2018).

Article  PubMed  Google Scholar 

Tang, M., Song, P. & He, J. Progress on drug pricing negotiations in China. Biosci. Trends 13, 464–468 (2019).

Article  PubMed  Google Scholar 

Zhang, Y. et al. Prices and clinical benefit of national price-negotiated anticancer medicines in China. PharmacoEconomics 40, 715–724 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Jommi, C., Armeni, P., Costa, F., Bertolani, A. & Otto, M. Implementation of value-based pricing for medicines. Clin. Ther. 42, 15–24 (2020).

Article  PubMed  Google Scholar 

Zhang, Y., Wagner, A. K. & Guan, X. Newly approved cancer drugs in China - innovation and clinical benefit. Nat. Rev. Clin. Oncol. 20, 135–136 (2023).

Article  PubMed  Google Scholar 

Yuan, J., Lu, Z. K., Xiong, X. & Jiang, B. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. BMJ Glob. Health 6, e005519 (2021).

Article  PubMed  PubMed Central  Google Scholar